This Biotech Just Flipped From Story to Execution ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Equiscreen._
-------------------------
AVAI IS TARGETING A TRILLION-DOLLAR PROBLEM WITH A NEW KIND OF
THERAPEUTIC PLATFORM!
[[link removed]]
As an early-stage company, AVAI BIO, INC. (OTC: AVAI)
[[link removed]] represents a developing story where
progress and milestones could play a key role in its value. Let’s
be real—the global health situation is getting intense.
DIABETES IS HITTING NEARLY 600 MILLION ADULTS TODAY AND CLIMBING FAST,
CARDIOVASCULAR DISEASE IS STILL THE TOP KILLER WORLDWIDE, AND CANCER
PLUS CHRONIC KIDNEY DISEASE ARE IMPACTING HUNDREDS OF MILLIONS MORE.
The common thread? Most treatments are stuck in “maintenance
mode,” managing symptoms instead of fixing what’s actually broken.
Meanwhile, the costs are skyrocketing—diabetes alone has crossed the
$1 trillion mark in healthcare spending. AVAI HAS A SOLUTION! The
company is focused on developing living-cell therapies designed to
restore essential biological functions lost to chronic disease.
AVAI IS TRYING TO FLIP THE SCRIPT. Instead of temporary fixes, the
company is DEVELOPING LIVING-CELL THERAPIES DESIGNED TO RESTORE CORE
BIOLOGICAL FUNCTIONS—THINK continuous insulin production and
longevity-focused protein delivery through advanced encapsulated cell
tech.
The company’s approach combines genetic engineering with cell
encapsulation to create protected, long-acting treatments. At its
core, AVAI engineers cell lines that can continuously produce key
therapeutic proteins inside the body.
The company is working to replace what the body no longer
produces—such as insulin or longevity-associated proteins—through
sustained cellular delivery. With a dual focus on diabetes and
age-related disease, AVAI is tapping into some of the fastest-growing
spaces in biotech, from cell therapy to longevity science.
IT’S A BOLD APPROACH AIMED AT SOLVING PROBLEMS AT THEIR SOURCE, NOT
JUST KEEPING THEM IN CHECK!
DISCOVER HOW AVAI IS MAKING NOISE AS A NEXT-GEN BIOTECH PLAYER TAKING
A SMARTER, MORE DURABLE SWING AT CHRONIC DISEASE AND THE FUTURE OF
HUMAN HEALTH! [[link removed]]
We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of Avant Technologies (OTCQB: AVAI). The compensation consists of up
to $7,500 and was received/will be received from Interactive Offers.
This communication should not be considered as an endorsement of the
securities of adviser Avant Technologies (OTCQB: AVAI) and we are not
responsible for any errors or omissions in any information provided
about the securities of Avant Technologies (OTCQB: AVAI) by Small Caps
Daily or Interactive Offers.
We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.
This disclosure is made as of 05/15/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]
Behind the Markets
[[link removed]]
_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._
